Thursday, October 12, 2017 8:06:56 PM
Analyst Jim Birchenough is bullish on the company following selection of IPI-549 monotherapy data as a late breaker oral presentation at SITC annual meeting next month. The analyst comments "Based on prior SITC late breaker data we see a reasonable likelihood of proof-of-concept response rate data, and with likely validation of tumor macrophage targeting in immunooncology (IO) and a unique mechanism of action we see upside potential not reflected at current stock price."
New York Yankees and Duke Basketball
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM